PE-22-28- is a short peptide fragment derived from DBI that modulates GABA-A receptors in the brain. It is non-sedative, non-addictive, and designed to mimic the anti-anxiety effects of benzodiazepines without their side effects or dependency risk.

Mechanism of Action

• Acts on GABA-A receptors at an allosteric site (similar to benzodiazepines but with different binding kinetics)

• Enhances GABAergic transmission, promoting calming and anxiolytic effects

• Does not bind directly to benzodiazepine receptor site, reducing potential for sedation or tolerance

Top Benefits of PE-22-28

🧠 Neurological & Cognitive Benefits

• Reduces anxiety without sedation or addiction potential

• Improves mood by enhancing GABA tone and balancing neurotransmitters

• Supports neurogenesis and neuronal plasticity

• Protects against neuroinflammation and oxidative stress

• May improve emotional resilience and stress tolerance

😴 Sleep & Relaxation

• Promotes relaxation and calm without causing drowsiness

• May improve sleep quality by reducing cortisol-driven arousal

🧬 Neuroprotective Effects

• Protects brain tissue from glutamate-induced excitotoxicity

• May aid in recovery from brain injuries, PTSD, or chronic stress states

💊 Alternative to Benzodiazepines

• Non-habit-forming and non-sedating

• No withdrawal symptoms reported in research settings

• May be a safe long-term option for anxiety management

Emerging Research & Applications

• PTSD, social anxiety, and generalized anxiety disorders (GAD)

• Adjunct for traumatic brain injury recovery

• Neurodegenerative disease prevention (being studied)

• Cognitive enhancement under high-stress conditions